34
Views
12
CrossRef citations to date
0
Altmetric
Case Reports

Adverse Interaction Between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters and Bleeding: Case Report and Review of the Literature

Pages 339-342 | Published online: 18 Jul 2013

References

  • Chu E, Mota AC, Fogarski MC. Antimetabolites. In: DeVita VI Jr, Hellman S, Rosenerg SA, eds. Cancer Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2001: 388–415.
  • Kolesar JM, Johnson CL, Freeberg BL, et al. Warfarin-5-FU interaction - a consecutive case series. Pharmacotherapy 1999; 19: 1445-1449.
  • Masci G, Magagnoli M, Zucali PA, et al. Minidose war-farin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003; 21: 736–739.
  • Reigner B, Blesch K, Weidekamm E. Clinical pharmaco-kinetics of capecitabine. Clin Pharmacokinet 2001; 40: 85–104.
  • Xeloda (capecitabine) Product monograph. Roche Pharmaceuticals. October 2004, pp 135-136.
  • Copur MS, Ledakis P, Bolton M, et al. An adverse inter-action between warfarin and capecitabine: A case report and review of the literature. Clin Colorectal Cancer 2001; 1: 182–184.
  • Buyck HCE, Buckley N, Leslie MD, Plowman PN. Capecitabine-induced potentiation of warfarin. Clin Oncol 2003; 15: 1 (correspondence).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.